Abstract
Over the past 20 years, the treatment armamentarium for diabetes has greatly expanded: 8 different classes of non-insulin drugs and 8 different types of insulin are now available. The newer classes of agents include disaccharidase inhibitors, thiazolidinediones, meglitinides, glucagonlike peptide analogs, and dipeptidyl peptidase IV inhibitors. These drugs offer advantages to certain patients when used as add-on (or first-line) therapy; however, metformin remains the preferred first-line oral agent. New long-acting insulin analogs provide more constant basal insulin coverage than neutral protamine Hagedorn (NPH) or lente insulin. Semisynthetic rapid-acting insulins help control prandial hyperglycemia with less risk of postprandial hypoglycemia than is seen with regular insulin. In addition to the many new pharmacological treatments for diabetes, the advent of continuous glucose monitoring permits relatively automated control of insulin pump administration.
| Original language | English |
|---|---|
| Pages (from-to) | 1113-1127 |
| Number of pages | 15 |
| Journal | Consultant |
| Volume | 47 |
| Issue number | 13 |
| State | Published - Nov 2007 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Diabetes : A primer on new drug options. / Rendell, Marc.
In: Consultant, Vol. 47, No. 13, 11.2007, p. 1113-1127.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Diabetes
T2 - A primer on new drug options
AU - Rendell, Marc
PY - 2007/11
Y1 - 2007/11
N2 - Over the past 20 years, the treatment armamentarium for diabetes has greatly expanded: 8 different classes of non-insulin drugs and 8 different types of insulin are now available. The newer classes of agents include disaccharidase inhibitors, thiazolidinediones, meglitinides, glucagonlike peptide analogs, and dipeptidyl peptidase IV inhibitors. These drugs offer advantages to certain patients when used as add-on (or first-line) therapy; however, metformin remains the preferred first-line oral agent. New long-acting insulin analogs provide more constant basal insulin coverage than neutral protamine Hagedorn (NPH) or lente insulin. Semisynthetic rapid-acting insulins help control prandial hyperglycemia with less risk of postprandial hypoglycemia than is seen with regular insulin. In addition to the many new pharmacological treatments for diabetes, the advent of continuous glucose monitoring permits relatively automated control of insulin pump administration.
AB - Over the past 20 years, the treatment armamentarium for diabetes has greatly expanded: 8 different classes of non-insulin drugs and 8 different types of insulin are now available. The newer classes of agents include disaccharidase inhibitors, thiazolidinediones, meglitinides, glucagonlike peptide analogs, and dipeptidyl peptidase IV inhibitors. These drugs offer advantages to certain patients when used as add-on (or first-line) therapy; however, metformin remains the preferred first-line oral agent. New long-acting insulin analogs provide more constant basal insulin coverage than neutral protamine Hagedorn (NPH) or lente insulin. Semisynthetic rapid-acting insulins help control prandial hyperglycemia with less risk of postprandial hypoglycemia than is seen with regular insulin. In addition to the many new pharmacological treatments for diabetes, the advent of continuous glucose monitoring permits relatively automated control of insulin pump administration.
UR - http://www.scopus.com/inward/record.url?scp=36448943542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36448943542&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:36448943542
VL - 47
SP - 1113
EP - 1127
JO - Consultant
JF - Consultant
SN - 0010-7069
IS - 13
ER -